Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸¶¿ì½ºÁ¾¾ç¿¡¼­ ºÐÇÒ¹æ»ç¼±Á¶»ç¿Í º´¿ëµÈ TirapazamineÀÇ È¿°ú¿¡ ¹ÌÄ¡´Â Á¾¾ç Àú»ê¼Ò»óÅÂÀÇ ¿µÇâ Effect of Tumor Hypoxia on Efficacy of Tirapazamine Combined with Fractionated Irradiation in Mouse Tumor

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 2È£ p.120 ~ 126
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀÏȯ/IL Han Kim

Abstract

¸ñÀû : Á¾¾ç³» Àú»ê¼Ò»óÅ´ Àú»ê¼Ò¼¼Æ÷Ä¡»çü¿¡ ÀÇÇÏ¿© ±Øº¹ÀÌ °¡´ÉÇÏ´Ù. ¹æ»ç¼±ÀÇ ¹ÝÀÀ
À» Áõ°­½ÃÅ°´Â tirapaza-mineÀÇ È¿°ú°¡ ¸¶¿ì½º Á¾¾ç¿¡¼­ ºÐÇÒ¹æ»ç¼±Á¶»ç¿Í º´¿ëµÈ »óÅ¿¡¼­
Á¾¾ç³» »ê¼Ò»óÅ¿¡ µû¶ó ¾î¶°ÇÑ ¿µÇâÀ» ¹Þ´Â°¡¸¦ È®ÀÎÇÏ°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : ´ëÁ¶±º ¹× Àú»ê¼Ò »óÅÂÀÇ Á¾¾çÀ» ¼ö¸³Çϱâ À§ÇÏ¿© Á¤»ó ¹× 4ÁÖÀü¿¡ ¹æ»ç
¼± Á¶»ç¸¦ ¹Þ¾Ò´ø ¸¶¿ì½ºÀÇ µî°ú ÇÏÁö¿¡ RIF-1 Á¾¾çÀ» À̽ÄÇÏ¿´´Ù. Á¾¾çÀÌ ÀÏÁ¤ÇÑ Å©±â¿¡
µµ´ÞÇϸé, ´ëÁ¶±º ¹× Àú»ê¼Ò »óÅ Á¾¾ç¿¡ ´ëÇÏ¿© »ý¸®½Ä¿°¼ö(0.02 mlg), tirapazamine (0.08
mM/kg), ¹æ»ç¼±Á¶»ç(2.5 Gy), tirapazamine °ú ¹æ»ç¼±Á¶»çÀÇ º´¿ë µîÀ» »ç¿ëÇÏ¿© 4ÀÏ°£ 8ȸ
ÀÇ °úºÐÇÒ Ä¡·á¸¦ ½ÃÇàÇÏ¿´´Ù. µîÀÇ Á¾¾çüÀûÀÌ 4¹è·Î Áõ°¡Çϰųª ÇÏÁöÀÇ Á¾¾ç ´Ü¸éÀÌ 2¹è
·Î Áõ°¡ÇÒ ¶§±îÁö Á¾¾çÀÇ Å©±â º¯È­¸¦ ÃøÁ¤ÇÏ¿© ¾òÀº Á¾¾ç¼ºÀåÀÇ Áö¿¬À» ±âÁØÀ¸·Î °¢ Ä¡·á
¿¡ ´ëÇÑ ¹ÝÀÀÀ» Æò°¡ÇÏ¿´´Ù.
°á°ú : µî ¹× ÇÏÁöÀÇ Á¤»ó ¹× Àú»ê¼ÒÁ¾¾çÀÇ Æò±ÕÁõ½Ä¾ç»óÀ¸·ÎºÎÅÍ tirapazamineÀÌ ¹æ»ç¼±
ÀÇ ¹ÝÀÀÀ» Áõ°­½ÃÄ×À½À» ¾Ë ¼ö ÀÖ´Ù. tirapazamine¿¡ ÀÇÇÑ ¹æ»ç¼±Áõ°­È¿°ú´Â ÃʱâÀÇ Á¶¾ç¿¡
¼­´Â 2.4¹è¿´À¸¸ç ÇÏÁöÀÇ Á¤»óÁ¾¾ç¿¡¼­´Â1.9¹è, Àú»ê¼ÒÁ¾¾ç¿¡¼­´Â 2.4¹è¿´À¸¸ç ÇÏÁöÀÇ Á¤»óÁ¾
¾ç¿¡¼­´Â 1.85¹è, Àú»ê¼ÒÁ¾¾ç¿¡¼­´Â 1.6¹è¿´´Ù. ÃʱâÁ¾¾çüÀûÀÇ 4¹è Áõ½Ä ¶Ç´Â Á¾¾ç´Ü¸éÀûÀÇ
2¹èÁõ½Ä±îÁöÀÇ ±â°£À» ±âÁØÀ¸·Î ¼³Á¤ÇÑ Áõ½ÄÁö¿¬½ÇÇè°á°ú µîÀÇ Á¤»óÁ¾¾ç¿¡¼­´Â 1.48¹è, Àú»ê
¼ÒÁ¾¾ç¿¡¼­´Â 2.02¹è¿´À¸¸ç ÇÏÁöÀÇ Á¤»óÁ¾¾ç¿¡¼­´Â1.85¹è, Àú»ê¼ÒÁ¾¾ç¿¡¼­´Â 1.6¹è¿´´Ù.
°á·Ð : ºÐÇÒ ¹æ»ç¼±Á¶»ç¿¡ tirapazamineÀ» º´¿ëÇÒ °æ¿ì ¹æ»ç¼±Á¶»çÈ¿°ú´Â Áõ°­µÇ¸ç, Àú»ê
¼Ò»óÅ¿¡ ÀÖ´Â ¸¶¿ì½º Á¾¾ç¿¡¼­ÀÇ Áõ°­È¿°ú°¡ ´ëÁ¶ Á¾¾ç¿¡¼­ÀÇ Áõ°­È¿°ú¿Í µ¿ÀÏÇϰųª ´õ¿í
¾çÈ£ÇÒ °¡´É¼ºÀ» Á¦½ÃÇÒ ¼ö ÀÖ¾ú´Ù.

Purpose : Tumor hypoxia can be overcome with hypoxic cytotoxin. In mouse tumor,
tirapazamine's efficacy of the potentiating radiation effect was tested by the tumor
oxygenation status combined with hyperfactionated radiotherapy.
Materials and Methods : The control and hypoxic mouse tumors were established by
inoculation of RIF-1 tumor cells into the normal or previously irradiated back and thigh
of C3H mice. When the tumors reached a proper size, both the control and hypoxic
tumor were given hyperfractionated treatments (8 fractions/4 days) with saline (0.02
ml/g), tirapazamin (0.08 mM/0.02 ml/kg), irradiation (2.5 Gy), irradiation combined with
tirapazamine given 30 minutes prior to each irradiation, The response was evaluated by
the growth delay assay by measuring tumor size form day 0 (12 hrs prior to the first
fractionation) to the day when the volume had 4-fold increase of cross sectional area
had 2-fold increase.
Results : Overall growth pattern showed that tirapazamine potentiated radiation effect
in back and thigh tumors grew in the normal and preirradiated tumor bed. With growth
delay assay using reference point of initial tumor volume of cross sectional area,
tirapazamine potentiated radiation effect 1.9 times for the control and 2.4 times for the
hypoxic tumors in back, and 1.85 times for the control and 1.6 times for the hypoxic
tumors. With reference of 4-fold increase of the initial volume or 2-fold increase of the
cross sectional area, tirapazamine potentiated radiation effect 1.48 times for the control
and 2.02 times for the hypoxic tumors in back, and 1.85 times for the control and 1.6
times for the hypoxic tumors.
Conclusion : Present result indicated that radiation response of hypoxic tumors was
potentiated by tirapazamine in the back or thigh tumors grew in the control or
preirradiated tumor bed, and potentiation of the hypoxic tumors was equal to or greater
than that of the control tumors in the back or thigh.

Å°¿öµå

Tumor hypoxia; Tirapazamine; Radiation; Growth delay;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS